AstraZeneca (AZN) CEO awarded 101,495 shares on AZPSP vesting

Rhea-AI Filing Summary

AstraZeneca PLC reported that Chief Executive Officer Pascal Soriot received ordinary shares following the vesting of a long-term incentive award under the AstraZeneca Performance Share Plan (AZPSP).

The AZPSP award, granted on 5 March 2021 with a three-year performance period and subsequent two-year holding period, vested on its fifth anniversary. Application of the original performance conditions led to 88% of the award vesting and the remainder lapsing. After dividend reinvestment and withholding of shares to cover tax obligations, Soriot acquired 101,495 ordinary shares on 5 March 2026 for nil consideration. For tax purposes, the fair market value at vest was 15,088 pence per share, based on the closing price on the previous trading day.

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of March 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Director/PDMR Shareholding

 6 March 2026

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announced that, on 5 March 2026, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to Pascal Soriot, Executive Director and Chief Executive Officer, under the terms of the AstraZeneca Performance Share Plan (AZPSP).

The AZPSP award was granted on 5 March 2021 and was subject to a three-year performance period. On the third anniversary of grant the award was placed in a two-year holding period. The award vested at the end of that holding period. Application of the performance measures specified at the time of grant resulted in 88% of the AZPSP award vesting and the remaining unvested part lapsing.

Following the reinvestment of dividends accrued during performance and holding periods of the AZPSP award, and the withholding of shares to satisfy certain tax obligations arising on vesting, Mr Soriot's beneficial interests in Ordinary Shares changed as detailed in the table below:

PDMR	Ordinary Shares acquired under the AZPSP
Pascal Soriot	101,495

For tax purposes, the fair market value of an Ordinary Share at vest of the AZPSP award was 15,088 pence, being the closing price on the last trading day preceding the vesting.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Pascal Soriot
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b)	Nature of the transaction	Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Performance Share Plan, for nil consideration.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		0	101,495
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	5 March 2026
f)	Place of the transaction	Outside a trading venue

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 06 March 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What did AstraZeneca (AZN) disclose about Pascal Soriot’s share award in March 2026?

AstraZeneca disclosed that CEO Pascal Soriot received ordinary shares from a vested AstraZeneca Performance Share Plan award. The grant, made on 5 March 2021, vested after a three-year performance period and a two-year holding period, with 88% of the award ultimately vesting.

How many AstraZeneca (AZN) shares did Pascal Soriot acquire from the AZPSP vesting?

Pascal Soriot acquired 101,495 AstraZeneca ordinary shares through the vesting of his AZPSP award. This followed reinvestment of dividends and withholding of some shares to meet tax obligations, resulting in a change in his beneficial interest in the company’s ordinary shares.

What performance outcome applied to Pascal Soriot’s 2021 AstraZeneca AZPSP award?

The 2021 AZPSP award for Pascal Soriot vested at 88% of the original grant. Performance measures set at grant were applied at vesting, causing 12% of the award to lapse, while the remaining 88% converted into AstraZeneca ordinary shares under the plan’s terms.

What was the fair market value per AstraZeneca (AZN) share at the time of the AZPSP vesting?

For tax purposes, the fair market value of each AstraZeneca ordinary share at vesting of the AZPSP award was 15,088 pence. This figure was based on the closing share price on the last trading day immediately before the vesting date in March 2026.

On what date did Pascal Soriot’s AstraZeneca Performance Share Plan award vest?

Pascal Soriot’s AZPSP award vested on 5 March 2026. The award was originally granted on 5 March 2021, featured a three-year performance period, and was then held in a further two-year holding period before vesting into AstraZeneca ordinary shares.

How was the nature and pricing of Pascal Soriot’s AstraZeneca share transaction described?

The transaction was described as an acquisition of ordinary shares pursuant to vesting under the AstraZeneca Performance Share Plan, for nil consideration. The structured notification confirms a single transaction with a volume of 101,495 shares and no purchase price paid by Pascal Soriot.